

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pentosan polysulfate sodium for treating bladder pain syndrome ID1364

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Consilient Health (pentosan polysulfate sodium) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Bladder and Bowel Community • Bladder and Bowel UK • Bladder Health UK • Kidney Care UK • Kidney Research UK • Muslim Council of Britain • National Kidney Federation • Pelvic Pain Support Network • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Continence Advice • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Renal Society • British Society of Urogynaecology • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians and Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicines • Society for DGH Nephrologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Aspire (iAluRil) • Galen (Uracyst) • Mylan (dimethyl sulfoxide) • Purple Orchid Pharma (Gepan) • Syner-Med (Hyacyst) • Teva (Cystistat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney and Transplant Group

Provisional matrix for the single technology appraisal of pentosan polysulfate sodium for treating bladder pain syndrome ID1364

Issue date: October 2018

© National Institute for Health and Care Excellence 2018. All rights reserved. Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Urology Foundation • United Kingdom Clinical Pharmacy Association • United Kingdom Continence Society • UK Health Forum • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Cambridgeshire and Peterborough CCG • NHS England • NHS Wigan Borough CCG • Welsh Government 	<ul style="list-style-type: none"> • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

Footers

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

